Thomas Smeenk provides an update on Hemostemix's ACP-01 stem cell treatment for heart disease

written by InvestorNews | January 6, 2023

Peter Clausi interviews Hemostemix Inc.'s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and CEO Thomas Smeenk about an update on their stem cell therapeutics to treat heart diseases and critical limb ischemia. Providing an update on the production timeline for ACP-01, Thomas discusses how Hemostemix has strengthened its scientific advisory board.

Thomas talks about the appointment of Dr. Nadia Giannetti and Dr. Renzo Cecere, two of the world's top cardiovascular physicians and stem cell scientists, as Co-Lead Medical Consultants, Cardiovascular Medicine and Clinical Trials. He explains how the recent addition to its scientific advisory board is a significant validation of ACP-01 to be "a first-to-patient approved therapeutic to treat heart disease and critical limb ischemia amongst other diseases of ischemia."

To access the full InvestorIntel interview, click here

Don't miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. Seven studies including 260 ACP-01 recipients define its safety and efficacy profile as a treatment for heart diseases such as Dilated and Ischemic Cardiomyopathy, Angina, and diseases of Ischemia such as Critical Limb Ischemia. The Company owns 91 patents across five patent families. For more information, please visit **www.hemostemix.com.**

To learn more about Hemostemix Inc., click here.

Disclaimer: *Hemostemix Inc. is an advertorial member of InvestorIntel Corp.*

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the

Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at info@investorintel.com.